NCT01613079.

BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50 | UCB

Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic

Objectives: To evaluate the efficacy and safety of izokibep, a small protein therapeutic designed to inhibit interleukin-17A, in patients with active psoriatic arthritis (PsA) over 46 weeks. Methods:…

In the double-blind, placebo-controlled phase 2 ARGO trial, patients with active psoriatic arthritis treated with a nanobody targeting IL-17A and IL-17F showed substantially better disease response…

Spyre Therapeutics (NASDAQ: SYRE) reported topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial of TL1A antibody SPY072. The low dose achieved a statistically significant improvement vs placebo on the primary endpoint DAS28-CRP at Week 12 (-1.9 vs -1.3; p<0.05). High-dose SPY072 showed nominally significant benefit on ACR20 (63% vs 43%), while low dose showed nominally significant benefit on ACR50 (38% vs 19%). Both doses reached target drug levels and provided complete suppression of free TL1A through Week 12, indicating full target engagement.SPY072 was well tolerated, with adverse events in 27% of active vs 36% of placebo patients, mostly mild or moderate; one serious TEAE occurred per arm, none drug-related, and one death occurred on placebo. Spyre said the efficacy magnitude did not meet its internal bar to prioritize SPY072 RA monotherapy, but the data support broader TL1A potential and ongoing trials in PsA, axSpA, ulcerative colitis and hidradenitis suppurativa, with multiple topline readouts expected from late 2026 through 2028.

MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab. | MoonLake Immunotherapeutics announced…

Artiva Biotherapeutics (Nasdaq: ARTV) reported second quarter 2026 results and clinical progress for lead NK-cell therapy AlloNK. At EULAR 2026, Phase 2a data in refractory rheumatoid arthritis (RA) showed 5 of 7 patients (71%) achieving ACR50 at six months, with no loss of response as of April 3, 2026.Across 55 safety-evaluable autoimmune patients treated with AlloNK plus rituximab, no CRS, ICANS, AlloNK-related serious adverse events or treatment discontinuations due to adverse events were observed, and Grade ≥3 infection rate was 2%. The FDA granted RMAT designation for AlloNK plus rituximab in refractory RA, and Artiva plans to initiate a Phase 3 registrational trial in approximately 150 refractory RA patients in the second half of 2026.Artiva completed an approximately $300 million underwritten offering in May 2026 and reported cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029. Q2 2026 research and development expenses were $21.9 million and net loss was $25.0 million, compared to $17.9 million and $21.3 million, respectively, in Q2 2025.

APEX 48-week topline findings 57% reduction in radiographic progression after placebo patients switched to Tremfya. Sustained ACR50 gains from week 24 to week 48 across both Q4W and Q8W dosing schedules. ~50% of switch patients reached ACR50 by week 48. Durable joint improvements maintained through 48 weeks. Safety consistent with Tremfya’s established profile; no new safety signals identified. Johnson & Johnson has shared new, long-term data from the Phase IIIb APEX clinical trial (NCT04882098) evaluating Tremfya (guselkumab) in active psoriatic arthritis (PsA).1…

APEX 48-week topline findings 57% reduction in radiographic progression after placebo patients switched to Tremfya. Sustained ACR50 gains from week 24 to week 48 across both Q4W and Q8W dosing schedules. ~50% of switch patients reached ACR50 by week 48. Durable joint improvements maintained through 48 weeks. Safety consistent with Tremfya’s established profile; no new safety signals identified. Johnson & Johnson has shared new, long-term data from the Phase IIIb APEX clinical trial (NCT04882098) evaluating Tremfya (guselkumab) in active psoriatic arthritis (PsA).1…

Artiva Biotherapeutics secured RMAT designation for its allogeneic NK cell therapy after Phase 2a data showed durable responses in refractory rheumatoid arthritis.

JOHNSON AND JOHNSONNipocalimab Shows Stronger Phase 2 Signal in Autoantibody-High Sjögren’s DiseaseNipocalimab is attracting attention at EULAR 2026 as a potential new option for patients with Sjögren...